Benzinga | May 20, 2021 06:30AM EDT

Baird Initiates Coverage On VistaGen Therapeutics with Outperform Rating, Announces Price Target of $9

Baird analyst Brian Skorney initiates coverage on VistaGen Therapeutics (NASDAQ:VTGN) with a Outperform rating and announces Price Target of $9.